Treating recurrent glioblastoma with sacituzumab govitecan
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests sacituzumab govitecan in adults whose glioblastoma has come back after standard treatment (radiation plus temozolomide). It may help shrink the tumor in people whose tumor has a specific target (Trop-2).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign study consent after understanding risks and goals.
- Your brain tumor diagnosis is IDH “wild type” glioblastoma (IDH-mutant is not allowed).
- Your tumor has grown or progressed after standard radiation and temozolomide treatment, or at least after standard radiation if MGMT is not methylated.
- You can skip Optune (tumor-treating fields) during the study, and your steroid dose has been stable or decreasing for 7 days before the first MRI.
- Recent MRI/CT shows measurable tumor, and the tumor must be Trop-2 positive by a central test (H-score 200 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This study tests a drug called sacituzumab govitecan for people with metastatic colorectal cancer who have already tried several standard treatments. It may be an option if your cancer is not MSI-H or dMMR and you haven't had irinotecan recently.
This trial tests a drug called sacituzumab govitecan for people with advanced thymic cancer (thymoma or thymic carcinoma) that has not responded to previous treatments. The goal is to see if the drug can shrink or slow the growth of the cancer.
This trial tests a drug called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma that has already been treated with chemotherapy and immunotherapy. The drug targets a protein called Trop-2 on cancer cells to try to stop tumor growth.
This study tests a drug called sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) for people with mesothelioma that has already been treated with other therapies. The goal is to see if the drug can shrink tumors and help control the disease.
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.